Welcome to our dedicated page for Crispr Therapeut news (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on Crispr Therapeut stock.
CRISPR Therapeutics AG reports developments in gene-based medicines built around CRISPR/Cas9 gene editing, cell therapy, in vivo editing and siRNA programs. Recurring updates cover CASGEVY, developed with Vertex for severe sickle cell disease and transfusion-dependent beta thalassemia, as well as pipeline work in cardiovascular disease, autoimmune disease, oncology, rare disease and Type 1 diabetes.
Company news also includes financial results, business updates, investor conference presentations, manufacturing and platform disclosures, collaborations such as Sirius Therapeutics, and capital actions involving common shares or convertible senior notes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
CRISPR Therapeutics (Nasdaq: CRSP) has announced participation in the 22nd Annual Needham Healthcare Conference, taking place virtually from April 17-20, 2023. The company's CEO, Sam Kulkarni, will present during a fireside chat on April 19, 2023, at 3:00 p.m. ET. The session will be accessible via a live webcast on the company's Investors page, and will be available for replay for 14 days post-event. CRISPR Therapeutics is recognized for its innovative approach in gene editing, leveraging the CRISPR/Cas9 technology to develop treatments for various serious diseases, including hemoglobinopathies, oncology, and rare diseases, in collaboration with partners like Bayer and Vertex Pharmaceuticals.